SCHEMBL1965544

SCHEMBL1965544

CC(C)(C)OC(=O)N(Cc1cccc(F)c1)n1cccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.47
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CTSS P25774 1/20 0.40
CTSK P43235 1/20 0.40
TSPO P30536 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
CLK1 P49759 1/20 0.39
CLK2 P49760 1/20 0.39
DYRK1A Q13627 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
GFER P55789 1/20 0.38
MAPT P10636 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
ALDH1A1 P00352 2/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1966131 0.86 KDM1A (0.42) RIPK1MEN1KMT2A
SCHEMBL1966223 0.85 ALDH1A1 (0.42) MEN1KMT2AGFERL3MBTL1ALDH1A1
SCHEMBL1965890 0.85 RIPK1 (0.47) RIPK1KMT2AL3MBTL1TSHRSMN1; SMN2
SCHEMBL1964950 0.84 AKT1 (0.46) RIPK1MEN1KMT2ACTSSL3MBTL1
SCHEMBL1964518 0.81 RIPK1 (0.46) RIPK1MAOB
SCHEMBL1965415 0.81 GPR119 (0.36) RIPK1CTSSCTSKGPR119ALDH1A1
SCHEMBL1965084 0.80 CTSB (0.40) MEN1KMT2ACTSSCTSK
SCHEMBL19950486 0.79 RIPK1 (0.51) RIPK1MEN1KMT2ACTSSCTSK
SCHEMBL1966228 0.79 MEN1 (0.41) MEN1KMT2AALDH1A1SMN1; SMN2MAOB
SCHEMBL1965400 0.78 GAA (0.40) MEN1KMT2AALDH1A1SMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 RIPK1 3787/4885MEN1 3904/4885KMT2A 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.